Ocugen's Participation in the Cell & Gene Meeting
Ocugen, Inc. (NASDAQ: OCGN), a prominent biotechnology company dedicated to innovative gene and cell therapies, has announced a significant upcoming presentation. Dr. Shankar Musunuri, Chairman and Chief Executive Officer, will take center stage at the 2024 Cell & Gene Meeting on the Mesa. This esteemed event is set to bring together industry leaders to discuss groundbreaking developments and strategies in translating science into viable treatments.
Overview of Dr. Musunuri's Presentation
Dr. Musunuri's presentation is expected to shed light on Ocugen's pioneering modifier gene therapy platform, a forefront solution aiming to tackle complex retinal diseases. The session will include insights into several key clinical trials, such as the Phase 3 liMeliGhT trial, focused on treating retinitis pigmentosa, along with the Phase 2 ArMaDa trial targeting geographic atrophy and the Phase 1/2 GARDian trial addressing Stargardt disease. With the Phase 3 trial currently in progress, Ocugen is on track to potentially meet its 2026 targets for Biologics License Application (BLA) and Marketing Authorization Application (MAA) approvals.
Importance of the Cell & Gene Meeting
The Cell & Gene Meeting on the Mesa serves as a crucial platform for industry stakeholders to converge and share knowledge on the latest advancements in regenerative medicine. The event emphasizes the urgent need for innovative solutions in areas where treatment options are scarce. Dr. Musunuri expressed the significance of this gathering, highlighting the role of the Alliance for Regenerative Medicine in championing new therapies that prioritize patient care and well-being.
Event Details
Details of the presentation are as follows:
Date: Monday, October 7, 2024
Time: 1:30 p.m. MST
Location: Arizona Biltmore, FLW, Ballroom F
For those unable to attend in person, virtual participation is available, including options for live streaming and on-demand viewing of all conference sessions.
About Ocugen, Inc.
Ocugen, Inc. is at the forefront of biotechnology, striving to transform patient care through innovative gene and cell therapies. The company is committed to making meaningful contributions to health by developing therapies that address unmet medical needs across various conditions. Ocugen's modifier gene therapy platform holds the potential to provide solutions for multiple retinal diseases with a single therapeutic product. In addition, the company is actively engaged in research aimed at enhancing public health through its work in infectious diseases and orthopedic conditions.
Connect with Ocugen
To learn more about Ocugen and its innovative therapies, visit www.ocugen.com. You can also follow the company on social media for the latest updates.
Frequently Asked Questions
What is the focus of Ocugen, Inc.?
Ocugen specializes in discovering and developing novel gene and cell therapies and vaccines to improve health outcomes.
Who will present at the 2024 Cell & Gene Meeting on the Mesa?
Dr. Shankar Musunuri, CEO of Ocugen, will present key insights on their gene therapy innovations.
What are the key clinical trials mentioned by Ocugen?
Ocugen highlighted three major trials: OCU400 Phase 3 liMeliGhT for retinitis pigmentosa, OCU410 Phase 2 ArMaDa for geographic atrophy, and OCU410ST Phase 1/2 GARDian for Stargardt disease.
When and where is the event taking place?
The event is set for October 7-9, 2024, at the Arizona Biltmore, with Dr. Musunuri's presentation scheduled for October 7 at 1:30 p.m. MST.
How can one participate virtually in the event?
Virtual attendance provides access to live streams and on-demand viewings of the conference presentations and sessions.
